Hyloris reports full year results for 2022 & provides
Strong R&D progress & attractive commercial deals, including additional Tranexamic Acid RTU out-licensing
Globe Newswire16-03-2023, 01:08
Impulse Dynamics Receives European CE Mark For Expanded Indication For Diastolic Heart Failure 28-03-2025, 19:00